Celltrion (068270) Q3 2025 earnings summary

Executive summary

• Achieved record quarterly sales exceeding KRW 1 trillion and operating profit over KRW 300 billion in 3Q25, driven by high-margin young biologics products.

• Biologics sales grew 18.7% year-over-year, with young products up 52.1% and now accounting for 54% of total biologics sales.

• Non-biologics sales declined due to the transfer of Takeda's primary care business rights, but impact was minimal at the group level.

Financial highlights

• 3Q25 sales: KRW 1,029 billion (+16.7% YoY, +7.0% QoQ); operating profit: KRW 301.4 billion (+45.1% YoY, +24.3% QoQ); OP margin: 29.3% (+4.1%p YoY).

• Net profit for 3Q25: KRW 332 billion, net profit margin: 32.3% (up 22.8%p YoY).

• Gross profit margin reached 60.8% in 3Q25, up 8.3%p YoY.

• COGS ratio improved to the low 30% range, first time post-merger.

Outlook and guidance

• Product mix expected to shift further toward high-margin young products in 4Q25 and beyond.

• Profitability anticipated to improve with additional launches (Eydenzelt, Avtozma) and expanded prescriptions for 2025 launches.

• COGS improvement trend expected to accelerate from 4Q25 onward.

• Five new product launches by end of 2025 to expand addressable market from $55B to $103B.